Codice QR

Therapeutic effect of TRC105 and decitabine combination in AML xenografts

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy, often characterized by poor prognosis following standard induction therapy. The hypomethylating agent decitabine (DAC) is an alternative treatment for elderly and relapsed/refractory AML patients, yet responses following DAC monot...

Descrizione completa

Salvato in:
Autori principali: June Baik, Martin Felices, Ashley Yingst, Charles P. Theuer, Michael R. Verneris, Jeffrey S. Miller, Rita Perlingeiro
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2020-10-01
Serie:Heliyon
Soggetti:
AML
TRC105
Decitabine
Xenografts
Cell biology
Antibody
Accesso online:http://www.sciencedirect.com/science/article/pii/S2405844020320855
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi